AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VOLITIONRX LTD Director's Dealing 2018

Jan 25, 2018

34395_dirs_2018-01-25_faa1976b-72e2-4555-a0b2-85c762295d98.zip

Director's Dealing

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2018-01-23

Reporting Person: Vanston David Cecil (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-23	Stock Option (Right to Buy)	$4	A	60000	Acquired	2024-01-23	Common Stock (60000)	Direct

Footnotes

F1: A total of 60,000 Options were granted on January 23, 2018 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.